Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 8, Number 5—May 2002

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

Thomas W. Geisbert*, Peter Pushko*, Kevin Anderson*, Jonathan Smith*, Kelly J. Davis*, and Peter B. Jahrling*
Author affiliations: *U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

Main Article

Table 1

Prechallenge neutralization titers of Ebola virus (EBOV)-vaccinated monkeys

Nonhuman primate species No. of animals Vector Antigen Neutralization titersa
Cynomolgus 3 Replicon GP 0, 0, 0
Cynomolgus 3 Replicon NP 0, 0, 0
Cynomolgus 3 Replicon GP + NP 0, 0, 10
Cynomolgus 3 Replicon Influenza HA 0, 0, 0
Cynomolgus 3 Vaccinia GP 10, 20, 20
Cynomolgus 3 Liposome Inactivated virion 20, 40, 80
Cynomolgus 2 Inactivated virion 10, 20
Rhesus 2 Inactivated virion 10b, 20
Cynomolgus 2 None 0, 0
Rhesus 2 None 0, 0

aImmunoglobulin G enzyme-linked immunosorbent assay, neutralizing antibody (PRNT50) All vaccinated monkeys seroconverted by enzyme-linked immunosorbent assay before challenge.
bAnimal survived challenge.
GP, glycoprotein; NP, nucleoprotein.

Main Article

Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.